Subtotal $0.00
Shop Now
GLP-1 hair loss is a recognized but uncommon side effect. In the trials behind the current U.S. labels, hair loss was reported in about 3% to 5% of adults taking Wegovy, Zepbound or Foundayo for weight management, compared with 1% to 2% on placebo, and it was far more common in women than in men. Each label says the hair loss was associated with weight reduction. Dermatologists recognize this pattern as telogen effluvium, temporary shedding that can follow rapid weight loss, and it usually improves with time. This guide covers the label figures, what 2026 studies found, other possible causes and when to talk to a clinician.
Peptide Labs does not sell GLP-1 medications or hair-loss products. This article does not recommend any product.
Key Takeaways
- Hair loss was reported in 3% to 5% of adults on Wegovy, Zepbound or Foundayo, versus 1% to 2% on placebo.
- Labels tie it to weight reduction, and women reported it far more often than men.
- Losing 20 pounds or more is a known trigger for temporary shedding called telogen effluvium.
- Two large 2026 observational studies linked GLP-1 use with a higher risk of non-scarring hair loss.
- Patchy loss, scalp symptoms or shedding that lasts beyond several months deserve a clinician's review.
Does GLP-1 cause hair loss? What the labels say
Hair loss appears in the adverse reaction tables of the GLP-1 medicines approved for weight management. The figures below come from the current prescribing information for each product. They come from separate trials, so they cannot be compared directly.
| Medicine (label revision) | Hair loss on the drug | Hair loss on placebo | Women vs men on the drug |
|---|---|---|---|
| Wegovy injection (June 2026) | 3.3% | 1% | 4% vs 0.9% |
| Wegovy HD, higher strength (June 2026) | 5.8% | 1.0% | 8.4% vs 0.2% |
| Wegovy injection, ages 12 to 17 (June 2026) | 4% | 0% | Not reported |
| Zepbound (August 2026) | 4% to 5% | 1% | 7.1% vs 0.5% |
| Foundayo (July 2026) | 4% to 5% | 2% | 7% vs 0.9% |
| Mounjaro (August 2026) | Not in the common-reaction table | Not applicable | Alopecia listed among postmarketing reports |
All three weight-management labels state that hair loss was associated with weight reduction. The Zepbound label adds that no one taking Zepbound in the main trials stopped the drug because of it. Diabetes labels such as Mounjaro’s do not list hair loss among common reactions, which fits the labels’ link to weight reduction; the Mounjaro label includes alopecia among reports received after approval, where frequency cannot be estimated. For the full side-effect picture, see our Wegovy side effects and Zepbound side effects guides.
Why weight loss can cause hair shedding
Each hair follicle cycles between a growing phase and a resting phase, after which the hair falls out. A physical stress can push many follicles into the resting phase at once, and a few months later they shed together. This is telogen effluvium. The American Academy of Dermatology lists losing 20 pounds or more among its triggers, alongside childbirth, high fever, surgery and major illness. According to the AAD, people usually notice the shedding a few months after the event, the shedding is temporary, and hair typically regains its normal fullness within six to nine months once the body readjusts. Telogen effluvium thins hair across the scalp; it does not scar the follicles or cause bald patches.
This is why the same shedding is seen after weight loss from bariatric surgery or strict diets, not only with GLP-1 drugs. Faster and larger weight loss, a sharp drop in food intake and low protein or micronutrient intake are all plausible contributors.
GLP-1 hair loss research from 2026
Two large observational studies published in 2026 looked for the link outside of trials:
- Journal of the American Academy of Dermatology (February 2026). Researchers at George Washington University used the TriNetX U.S. health-records network to compare 547,993 adults who filled GLP-1 prescriptions between 2014 and 2024 with matched non-users. At 12 months, GLP-1 users had higher adjusted odds of telogen effluvium (1.76), androgenetic alopecia, or pattern hair loss (1.64), and non-scarring hair loss overall (1.40).
- The BMJ (July 2026). A University of Pennsylvania team emulated a trial in adults with type 2 diabetes, comparing about 12,000 people starting a GLP-1 medicine with people starting SGLT2 inhibitors or DPP-4 inhibitors. GLP-1 users had a 37% and 68% higher risk of hair loss, respectively. In absolute terms, that was about 6.9 cases per 1,000 person-years, versus 5.0 and 3.9, or 2 to 3 extra cases per 1,000 people per year. The link was specific to non-scarring hair loss.
Both studies used health records, so they show an association, not proof that the drugs cause hair loss, and other differences between the groups could play a part. A University of Cambridge researcher commenting on the BMJ study called it well conducted but noted it cannot establish causation or show whether the hair loss reversed. The BMJ authors suggested rapid weight loss and nutritional changes as the likely drivers.
Other possible contributors
Hair loss while taking a GLP-1 medicine is not always caused by the medicine or by weight loss. Other common causes include:
- Low nutrient intake. A 2025 joint advisory from four obesity and nutrition societies warned that eating much less on GLP-1 therapy can lead to shortfalls in protein, iron, zinc and several vitamins.
- Thyroid problems, iron deficiency and hormonal changes, including menopause and stopping birth control pills.
- Pattern hair loss, which is gradual and runs in families, and may simply become noticeable during the same period.
- Other medicines, recent illness, surgery or major stress.
Because several of these can overlap, a clinician may check blood counts, iron stores, thyroid function or other labs rather than assume the GLP-1 medicine is responsible. A dermatologist can also examine the scalp and the pattern of loss, which often tells shedding apart from other types of hair loss that need different care.
When to talk to a clinician
Mild, even shedding a few months after starting is consistent with telogen effluvium, but it is still worth mentioning at your next visit. Contact the prescriber or a dermatologist sooner if you notice bald patches, redness, scaling, pain or itching on the scalp, shedding that continues beyond about six months, loss of eyebrows or body hair, or signs of poor nutrition such as fatigue, dizziness or very low food intake. Do not stop or change a prescription medicine on your own; the prescriber can review your rate of weight loss, diet and other causes, and decide whether any change makes sense. Our semaglutide and tirzepatide side-effect guides list what else to report.
Frequently Asked Questions
Does GLP-1 cause hair loss?
Hair loss was reported in about 3% to 5% of adults taking Wegovy, Zepbound or Foundayo in trials, versus 1% to 2% on placebo. The labels say it was associated with weight reduction.
Is GLP-1 hair loss permanent?
Shedding linked to weight loss, telogen effluvium, is usually temporary. The American Academy of Dermatology says hair typically regains its fullness within six to nine months.
Why do women report more hair loss on GLP-1 drugs?
The labels show much higher rates in women, but they do not explain why. Hormonal factors and differences in who enrolled in trials may play a part.
Which GLP-1 causes the most hair loss?
Label rates come from separate trials and cannot be ranked. Within the Wegovy trials, hair loss was more common with the higher-strength Wegovy HD than with standard Wegovy.
When does GLP-1 hair loss start?
Telogen effluvium typically appears a few months after the trigger, so shedding often shows up several months into weight loss rather than right away.
Should I stop my GLP-1 medicine if my hair is thinning?
Not without talking to the prescriber. In the Zepbound trials, no one stopped because of hair loss, and a clinician can check for other causes.
This article is general information, not medical advice. Peptide Labs does not sell prescription drugs, including any medicine named here. Ask a pharmacist or prescriber how this information applies to you.
Last reviewed September 2026.
Related guides: GLP-1 Diet: What Experts Recommend While on GLP-1 Medicines, Zepbound Side Effects: What the Latest Zepbound Label Reports, Wegovy Side Effects: Injection, Pill, Teens and Wegovy HD, GLP-1 Side Effects: What Every GLP-1 Drug Label Warns About, Collagen for Hair: Does It Help Hair Growth or Hair Loss?, Biotin Side Effects, Benefits and the Lab Test Problem, Hair Growth Vitamins: Do Hair Vitamins Work, and Who Needs Them?.